Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool March 27, 2008 Brian Orelli	Tougher Rules Could Help Stent Makers The FDA has finally issued draft guidance on the minimum requirements that it thinks companies need to fulfill to get drug-eluting stents approved.
The Motley Fool May 28, 2009 Anders Bylund	Of Robots and Rocket-Powered Returns Intuitive Surgical is a stock that meets your need for speed and security, all at once.
The Motley Fool January 11, 2008 Brian Orelli	Boston Scientific Lives Below Its Means Cost-cutting efforts should help turn the medical-device making company around in 2008.
The Motley Fool October 16, 2008 Brian Orelli	Foolish Forecast: Robots on the Cheap Intuitive Surgical releases earnings in a few hours. Here are some premonitions to tide you over as you anxiously wait the news.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool February 5, 2008 Brian Orelli	Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S.
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.
The Motley Fool September 25, 2008 Brian Orelli	Uh-Oh, Stent Makers Drugs are just as good as stents.
The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool June 13, 2008 Colleen Paulson	6 Cash Cows That Show Dad the Money Make your father proud by picking stocks with no debt and lots of cash.
The Motley Fool August 24, 2010 Brian Orelli	Disaster in Medical-Device Land Industry bellwether Medtronic is forecasting a nasty storm.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool October 31, 2006 Michael P. Cecil	An Opening for Plavix New data suggesting problems with drug-eluting stents may translate into more sales of the blood thinner Plavix and fewer sales of the stents. Investors, take note.
The Motley Fool November 17, 2006 Brian Lawler	Johnson & Johnson's Good Deal If Conor's stent design can alleviate some of the perceived safety worries about stents, then sales from the Cordis division should spring back up, again making it drive revenue growth for Johnson & Johnson, as it did before this year. Investors, take note.
The Motley Fool February 5, 2008 Brian Orelli	Boston Scientific Gets Charged Walloped by charges, Boston Scientific posts a loss for the quarter.
BusinessWeek December 6, 2004 Gene G. Marcial	Boston Scientific: Anemic -- For Now Boston Scientific is far from robust -- since its summer recall of 100,000 coronary stents and since its lowered fourth-quarter profit forecast. Analysts quickly cut estimates, driving shares down from 46 in May to 33.36 on Nov. 23.
The Motley Fool April 28, 2006 Stephen D. Simpson	Of Intuition and Intuitive Surgical Price has decoupled from value, but the company is growing like a weed. Investors, take note.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool November 7, 2007 Billy Fisher	SurModics Serves Up a Big Quarter The drug delivery technology company reports record revenue and operating cash flow in its fiscal fourth quarter.
The Motley Fool October 27, 2008 Brian Orelli	Hansen Medical Bucks the Trend The credit crunch doesn't seem to be having much of an effect on Hansen's ability to sell its products to hospitals.
The Motley Fool October 13, 2008 Brian Orelli	Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier.
The Motley Fool December 6, 2007 Brian Orelli	An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off?
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool February 8, 2011 Brian Orelli	What Will Intuitive Surgical Do for an Encore? Intuitive Surgical managed just a 10% year-over-year increase in revenue from sales of its da Vinci Surgical Systems in the fourth quarter of last year. Yet its total revenue increased a solid 21%. How?
The Motley Fool March 31, 2010 Brian Orelli	How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain.
The Motley Fool July 25, 2011 Brian Stoffel	My Money Is On This Hot Medical Stock Intuitive Surgical is blazing new paths for surgical procedures.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock.
The Motley Fool October 19, 2011 Brian Orelli	This High-Tech Company Still Has the Touch Intuitive Surgical beats analysts' expectations. Again.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool March 6, 2009 Brian Orelli	Why the Buyback, Intuitive Surgical? Buybacks for high-growth companies like Intuitive Surgical aren't such a bad idea anymore.
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool May 29, 2008 Brian Orelli	Medtronic Sticks It to Boston Scientific Medtronic wins the medical-device patent duel with Boston Scientific.
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
The Motley Fool April 15, 2009 Brian Orelli	Abbott's on Sale Abbott isn't firing on all cylinders the way it was last year, but things still look fine, and the stock is selling at a discount right now.
The Motley Fool January 13, 2012 Dan Caplinger	Has Intuitive Surgical Become the Perfect Stock? What Intuitive Surgical needs to do to get even closer to perfection is to get to the point in its growth curve at which it's ready to start paying dividends.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool February 23, 2009 Brian Orelli	Why Do You Hate Health-Care Companies So Much? Members of Congress plan to introduce a bill that would give patients legal recourse against medical device companies making drug-eluting stents, essentially nullifying a previous Supreme Court decision.
The Motley Fool April 20, 2005 Stephen D. Simpson	A Healing Look at Bard Medical device maker C.R. Bard shows that boring can be beautiful so long as boring pays the bills. Investors, take note.
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool August 26, 2008 Brian Orelli	Rapid Exchange of Fire Competitors try to block Abbott's patent extension.